Close Menu

    Subscribe to Updates

    Get the latest information from JBUON.

    What's Hot

    Two Cases of Pancreatic Metastases from Renal Cell Carcinoma and Review of the Literature

    April 17, 2025

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    March 14, 2025

    Surgical Treatment of Right Atrial Metastasis of the Malignant Melanoma: A Case Report

    March 6, 2025
    Facebook X (Twitter) Instagram
    JBUONJBUON
    • How to Submit
    • Author Guidelines
    Facebook X (Twitter) Instagram
    SUBMIT
    • Home
    • Browse Issues
      • In Press
      • Current Issue
      • Archives
    • About Journal
      • Journal Information
      • Editorial Board
      • Bibliographic Listings
      • Editorial Policy
      • Ethics and Malpractice Statement
    • For Authors
      • How To Submit
      • Submit Article
      • Downloads
    • Contact
    JBUONJBUON
    Home»Issues»Volume 26, Issue 6»PCGEM1 triggers liver cancer progression by positively regulating SNAI1
    Volume 26, Issue 6

    PCGEM1 triggers liver cancer progression by positively regulating SNAI1

    December 1, 2021Updated:April 29, 20242 Mins Read
    Share
    Facebook Twitter Email

    Yong Wang, Chen Chen, Xintian Wang, Chao Jiang

    Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China

    Summary

    Purpose: To uncover the biological role of long non-coding RNA (lncRNA) PCGEM1 in regulating the progression of liver cancer and the molecular mechanism.

    Methods: PCGEM1 levels in clinical specimens of liver cancer and cell lines were detected by quantitative real-time polymerase chain reaction (qRT-PCR). By analyzing the pathological data of recruited patients, the influences of PCGEM1 on tumor node metastasis (TNM) staging, tumor grading, lymphatic metastasis, and overall survival of liver cancer patients were assessed. Hep3B and Huh7 cells were transfected with si-PCGEM1, followed by detection of proliferative, migratory, and invasive rates through 5-Ethynyl-2’- deoxyuridine (EdU), cell counting kit-8 (CCK-8), and transwell assay. The interaction between PCGEM1 and SNAI1 was explored, and the biological functions of SNAI1 in liver cancer cell behaviors were finally detected.

    Results: PCGEM1 and SNAI1 were upregulated in clinical specimens of liver cancer and cell lines. High levels of PCGEM1 were detected in liver cancer cases with advanced staging, grading, or lymphatic metastasis, which predicted poor prognosis of liver cancer patients. Knockdown of PCGEM1 reduced proliferative, migratory, and invasive rates in Hep3B and Huh7 cells. SNAI1 was upregulated in liver cancer tissues and positively correlated with PCGEM1. Knockdown of SNAI1 also suppressed proliferative and metastatic potentials in Hep3B and Huh7 cells.

    Conclusions: LncRNA PCGEM1 triggers liver cancer cells to proliferate, migrate, and invade by upregulating SNAI1.

    Keywords: liver cancer, PCGEM1, SNAI1, proliferation, metastasis.

    Full Text: PDF

    Original Article
    Previous ArticleNon-alcoholic fatty liver disease and extra-hepatic malignancies
    Next Article LncRNA00978 contributes to cells growth and metastasis in hepatocellular carcinoma via mediating miR-125b-5p/SOX12 pathway

    Related Articles

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    Volume 27, 2024

    Malignant Diseases as a Reason for Interventions by Emergency Medical Teams in Barajevo 2023

    Volume 27, 2024

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    Volume 26, Issue 6
    Don't Miss
    Volume 27, 2024

    Two Cases of Pancreatic Metastases from Renal Cell Carcinoma and Review of the Literature

    April 17, 2025

    Dimosthenis Chrysikos1, Spiros Delis2, Charina Triantopoulou2, Evgenia Charitaki2, Nikos Kokoroskos2, Nikolaos Taprantzis1*, Amir Shihada1, Konstantinos…

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    March 14, 2025

    Surgical Treatment of Right Atrial Metastasis of the Malignant Melanoma: A Case Report

    March 6, 2025

    Abdominal Aortic Aneurysm and Radiation Therapy

    October 28, 2024
    Our Picks

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    December 1, 2021

    Chromosomal instability landscape in uveal melanoma

    December 1, 2021

    Biomarkers and common oral cancers: Clinical trial studies

    December 1, 2021

    Subscribe to Updates

    About Us
    About Us

    Journal of BUON (Print ISSN: 1107-0625, Electronic ISSN: 2241-6293) is an independent Open Access Journal, published by BAKIS Productions LTD, and appears exclusively on the internet. It is covered/indexed in Current Awareness in Biological Sciences (BIO-BASE), EMBASE/Excerpta Medica.
    We're accepting new manuscripts right now.

    Email Us: editorial_office@jbuon.com
    Contact: Available soon

    Editorial Picks

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    December 1, 2021

    Chromosomal instability landscape in uveal melanoma

    December 1, 2021

    Biomarkers and common oral cancers: Clinical trial studies

    December 1, 2021
    Get in Touch

    Editor-in-Chief
    Athanasios E. Athanasiou,
    Department of Medical Oncology,
    Metaxa Cancer Hospital, Botassi 51, 18537, Piraeus, Greece
    Editorial Office: editorial_office@jbuon.com

    Publishing support
    EManuscript Technologies
    # 9, First Floor, Vinnse Towers
    Wheeler Road Extension, St. Thomas Town, Bangalore 560 084, INDIA
    E: journals@emanuscript.in 
    W : www.emanuscript.in

     

    • Home
    • Author Guidelines
    • Site Map
    • Contact Us
    © 2025 JBUON Powered by EManuscript.

    Type above and press Enter to search. Press Esc to cancel.